Breast cancer accounts for >12% of all new cancer diagnoses and almost 10% of all cancer deaths in the United States.1 Receptor Logic has developed TCRm antibodies as a new platform for mAb therapeutics that are remarkably effective in addressing cancer and pathogen infections. The mAb market represents the fastest growing segment in the pharmaceutical industry, generating $35 billion per year worldwide in 2008 revenue and is expected to grow at a >10% CAGR through 2013.

Receptor Logic is headquartered in Abilene, Texas. The Development Corporation of Abilene (DCOA) and the DevelopAbilene Team, a consortium of Abilene economic development partners, offers a framework of support for SBIR/STTR research conducted primarily in Abilene. Companies may receive up to $5,000 for application preparation. For Phase 1 awards such as Receptor Logic has received from the National Cancer Institute, the DCOA matches grants at 10%, not to exceed $10,000. Accordingly, the DCOA has given Receptor Logic $10,000 as an incentive payment for funds received through the STTR award. Phase 2 SBIR/STTR grants are matched at 10%, not to exceed $75,000.

DCOA Chief Executive Officer Richard Burdine said, ???Our strategy is to bolster Abilene-based life sciences companies by providing additional funding that is not subject to the use limitations of a federally-funded grant and acts as a catalyst for more rapid business growth.???

www.receptorlogic